Universal or targeted screening for fetal alcohol exposure: a cost-effectiveness analysis

Area of Science:

• Pharmacoeconomics
• Clinical Chemistry
• Maternal-Fetal Medicine

Background:

• Therapeutic drug monitoring is infrequently assessed for its cost-saving potential.
• Fetal Alcohol Spectrum Disorder (FASD) presents significant management challenges.
• Meconium analysis offers a method for assessing in utero substance exposure.

Purpose of the Study:

• To critically appraise the cost-effectiveness of meconium analysis for fatty acid ethyl esters (FAEEs) in managing FASD.
• To evaluate the economic impact of implementing FAEE testing in clinical practice.
• To summarize findings from Hopkins et al. regarding FAEE testing and FASD management.

Main Methods:

• Critical appraisal of existing literature on the cost-effectiveness of meconium analysis for FAEEs.
• Review of studies examining the management of Fetal Alcohol Spectrum Disorder.
• Analysis of economic data related to diagnostic testing and FASD interventions.

Main Results:

• The cost-effectiveness of meconium analysis for FAEEs in FASD management is rarely evaluated.
• The article by Hopkins et al. provides a critical appraisal of this specific diagnostic approach.
• Potential cost savings associated with this monitoring method are explored.

Conclusions:

• Meconium analysis for FAEEs may offer a cost-effective strategy in the management of Fetal Alcohol Spectrum Disorder.
• Further research into the economic benefits of therapeutic drug monitoring for FASD is warranted.
• The findings highlight the importance of evaluating diagnostic tools for both clinical efficacy and economic impact.